Abstract: Compositions of engineered extracellular vesicles for delivery of cargo to targeted tissues and cells are described herein. Also described herein are methods for making and using the extracellular vesicles described herein. Lastly, described herein are methods for treating a subject, the method comprising administering to a subject an extracellular vesicle as described herein.

Abstract: Compositions and methods for modified viral vectors which mitigate the immunogenicity of viral vectors, enabling multiple administrations of viral-based gene delivery viral vectors are described herein. The viral vectors advantageously possess low immunogenicity and comprise at least one immunosuppressive moiety. Also described herein are methods for introducing genetic material into a cell. Additionally, described herein are methods for preparing a modified viral vector. Lastly, described herein are methods for treating a subject, the method comprising administering to a subject a modified viral vector composition as described above.

Abstract: Provided are compositions and methods for the production of modified endonucleases such as CRISPR/Cas9 system with reduced off-target activity. Methods of editing of polynucleotides using the modified endonucleases in vitro and in vivo are also disclosed. In one aspect, the disclosure provides a modified endonuclease, comprising an endonuclease and one or more mixed charge moieties covalently linked to the endonuclease, wherein each mixed charge moiety comprises about 10 to about 400 positively charged moieties and about 10 to about 400 negatively charged moieties, and wherein the ratio of the number of positively charged moieties to the number of negatively charged moieties is from about 1 :0.5 to about 1 :2.

Abstract: Charged polypeptides, their conjugates, and fusion proteins comprising such polypeptides are disclosed. Inclusion of such a polypeptide in a fusion protein increases the protein's properties such as stability and circulation half-life, which results in a better therapeutic efficacy compared to an active protein alone. Thus, a fusion protein or a conjugate of the disclosure can be useful in developing a protein or peptide drug, treating or preventing diseases, disorders, or conditions, or improving a subjects health or wellbeing.